Showing 3561-3570 of 4062 results for "".
- Verana Health: Study Demonstrates Promise of Real-World Data in Ophthalmic Clinical Developmenthttps://modernod.com/news/verana-health-study-demonstrates-promise-of-real-world-data-in-ophthalmic-clinical-development/2479172/Verana Health unveiled research during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. In a first-of-its kind study, Verana Health demonstrated that it was able to successfully use
- CooperVision Expands Prescription Options for Biofinity XR Toric Contact Lenseshttps://modernod.com/news/coopervision-expands-prescription-options-for-biofinity-xr-toric-contact-lenses/2479170/CooperVision is introducing a broader range of expanded parameters for its Biofinity XR toric lenses. The addition of sphere powers from ±10.50D to ±20.00D nearly doubles the number of available prescription options specific to this lens, making it easier for eye care professionals to fit patient
- Ocular Therapeutix Fulfills Post-Marketing Approval Requirements for ReSure Sealanthttps://modernod.com/news/ocular-therapeutix-fulfills-post-marketing-approval-requirements-for-resure-sealant/2479164/Ocular Therapeutix has received notification from the FDA confirming it has fulfilled all post-approval study requirements for ReSure Sealant, with a requirement to update the ReSure label reflecting the study results. As a condition for ReSure’s pre-market approval application (PMA) in 2014, the
- Nicox’s Licensee Bausch + Lomb Launches Vyzulta in Taiwan and Receives Approval in Qatarhttps://modernod.com/news/nicoxs-licensee-bausch-lomb-launches-vyzulta-in-taiwan-and-receives-approval-in-qatar/2479163/Nicox SA announced that its exclusive global licensee Bausch + Lomb has launched Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% in Taiwan. Regulatory approval in Taiwan was obtained in March 2020. Vyzulta has also recently received approval in Qatar. In addition to Taiwan, Vyzul
- Tarsus Pharmaceuticals Presents Results of Atlas Study Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-presents-results-of-atlas-study-demonstrating-the-functional-and-psychosocial-impact-of-demodex-blepharitis/2479161/Tarsus Pharmaceuticals announced data from its Demodex blepharitis clinical program presented at the virtual Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. Tarsus’ lead product candidate, TP-03, is a topical ophthalmic formulation of lotilaner, a well-characteriz
- Lineage Cell: OpRegen Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With GAhttps://modernod.com/news/lineage-cell-opregen-clinical-data-continues-to-demonstrate-improvements-in-patients-with-dry-amd-with-ga/2479160/Lineage Cell Therapeutics announced that updated interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen, were reported at the 2021 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2021). OpRegen is an investigational
- jCyte Identifies Predictive Biomarker for jCell Therapy in Largest Phase 3 Study for Retinitis Pigmentosahttps://modernod.com/news/jcyte-identifies-predictive-biomarker-for-jcell-therapy-in-largest-phase-3-study-for-retinitis-pigmentosa/2479157/jCyte announced presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, identifying a predictive biomarker for the upcoming phase 3 study for jCell therapy in retinitis pigmentosa. A detailed analysis by the Cleveland Clinic Cole Eye Institute
- Samsung Bioepis Announces Analytical Similarity Data on SB11 (Ranibizumab) at ARVOhttps://modernod.com/news/samsung-bioepis-announces-analytical-similarity-data-on-sb11-ranibizumab-at-arvo/2479155/Samsung Bioepis announced results from a study analyzing structural and functional similarity between SB11, a proposed ranibizumab biosimilar, and Lucentis (ranibizumab). The study results will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2021
- Refractive Surgery Council Reports Nearly 30% Rise in Laser Vision Correction Procedures Year over Yearhttps://modernod.com/news/refractive-surgery-council-reports-nearly-30-rise-in-laser-vision-correction-procedures-year-over-year/2479148/The Refractive Surgery Council (RSC), which helps consumers make informed choices about their vision correction options, reported a strong start to 2021 with a nearly 30 percent rise in laser vision correction (LVC) procedures year over year. More than 220,000 LASIK, SMILE and PRK procedures hav
- The Countess of Wessex Praises Work of Sight-Saving Charity Orbis During Pandemichttps://modernod.com/news/the-countess-of-wessex-praises-work-of-sight-saving-charity-orbis-during-pandemic/2479147/On April 28, 2021, Her Royal Highness The Countess of Wessex spoke in support of international eye care charity Orbis, at a virtual event to discuss delivering eye care to those most in need during the COVID-19 outbreak.